UA98983C2 - Антитіло проти гепсидину та його застосування - Google Patents

Антитіло проти гепсидину та його застосування

Info

Publication number
UA98983C2
UA98983C2 UAA201005156A UAA201005156A UA98983C2 UA 98983 C2 UA98983 C2 UA 98983C2 UA A201005156 A UAA201005156 A UA A201005156A UA A201005156 A UAA201005156 A UA A201005156A UA 98983 C2 UA98983 C2 UA 98983C2
Authority
UA
Ukraine
Prior art keywords
antibody
hepcidin antibodies
relates
vector
pharmaceutical composition
Prior art date
Application number
UAA201005156A
Other languages
English (en)
Russian (ru)
Inventor
Юйпін Ентоні Цай
Денніс Патрік Гейтлі
Лухун Хе
Донмайєнн Дон Льюнг
Пен Луань
Барбара Енн Свенсон
Їнь Тань
Деррік Райан Уітчер
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA98983(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA98983C2 publication Critical patent/UA98983C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Винахід належить до ізольованого антитіла, яке зв’язує людський гепсидин-25 з високою афінністю, полінуклеотиду, що його кодує, вектора, клітини-хазяїна, способу одержання антитіла. Винахід також належить до фармацевтичної композиції, що містить дане антитіло, застосуванню антитіла для лікування анемії, способу підвищення сироваткового заліза та набору для проведення імунологічного аналізу.
UAA201005156A 2007-11-02 2008-10-29 Антитіло проти гепсидину та його застосування UA98983C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98491007P 2007-11-02 2007-11-02
PCT/US2008/081493 WO2009058797A1 (en) 2007-11-02 2008-10-29 Anti-hepcidin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
UA98983C2 true UA98983C2 (uk) 2012-07-10

Family

ID=40383701

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201005156A UA98983C2 (uk) 2007-11-02 2008-10-29 Антитіло проти гепсидину та його застосування

Country Status (34)

Country Link
US (3) US7820163B2 (uk)
EP (2) EP2527368B1 (uk)
JP (1) JP5469076B2 (uk)
KR (2) KR20120107145A (uk)
CN (1) CN103492414B (uk)
AR (1) AR069062A1 (uk)
AU (1) AU2008318850B2 (uk)
BR (1) BRPI0819211A2 (uk)
CA (1) CA2704527C (uk)
CL (2) CL2008003190A1 (uk)
CO (1) CO6231037A2 (uk)
CR (1) CR11414A (uk)
CY (1) CY1113630T1 (uk)
DK (1) DK2209806T3 (uk)
DO (2) DOP2010000123A (uk)
EA (1) EA023406B1 (uk)
ES (1) ES2392123T3 (uk)
HR (1) HRP20120870T1 (uk)
IL (1) IL205355A (uk)
JO (1) JO2828B1 (uk)
MA (1) MA31886B1 (uk)
MX (1) MX2010004841A (uk)
MY (1) MY155708A (uk)
NZ (2) NZ584997A (uk)
PE (1) PE20091261A1 (uk)
PL (1) PL2209806T3 (uk)
PT (1) PT2209806E (uk)
RS (1) RS52592B (uk)
SI (1) SI2209806T1 (uk)
TN (1) TN2010000201A1 (uk)
TW (1) TWI409276B (uk)
UA (1) UA98983C2 (uk)
WO (1) WO2009058797A1 (uk)
ZA (1) ZA201003025B (uk)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047485A1 (en) * 2006-10-17 2008-04-24 Naohisa Tomosugi Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator
AR065083A1 (es) 2007-02-02 2009-05-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
WO2008146903A1 (ja) * 2007-05-31 2008-12-04 Naohisa Tomosugi 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法
CL2008003190A1 (es) * 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
JP2011519279A (ja) * 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
US8609817B2 (en) * 2008-08-06 2013-12-17 Eli Lilly And Company Anti-hepcidin-25 selective antibodies and uses thereof
DE102009034150A1 (de) 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
BR112012003701A2 (pt) 2009-08-20 2019-09-24 Vifor Int Ag "novos antagonistas de quinolina-hepcidina"
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
BR112012005119A2 (pt) 2009-09-07 2016-11-22 Vifor Int Ag novos antagonistas de hepcidina etanodiaminas
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
WO2011071368A1 (en) 2009-12-11 2011-06-16 Umc St. Radboud Method for measuring hepcidin
CN103154023B (zh) 2010-08-16 2017-04-05 皮里斯制药有限公司 铁调素的结合蛋白
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
US9610356B2 (en) 2011-12-12 2017-04-04 Pieris Pharmaceutical GmbH Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
EP2968503B1 (en) * 2013-03-15 2018-08-15 Intrinsic LifeSciences LLC Anti-hepcidin antibodies and uses thereof
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CN104945497B (zh) * 2014-11-21 2018-04-03 南京国龙生物科技有限公司 一种新型抗菌肽Hep‑W及其制备方法和应用
EP3261670A4 (en) 2015-02-24 2018-08-01 Rpeptide, LLC Anti-tau antibodies
US11203753B2 (en) 2015-03-13 2021-12-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonists for use in the treatment of inflammation
TWI789343B (zh) 2016-02-01 2023-01-11 丹麥商碩騰丹麥有限公司 微流體分析系統、執行分析的微流體匣及方法
WO2018234538A1 (en) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism
ES2759622T3 (es) * 2017-10-02 2020-05-11 Certest Biotec S L Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
WO2021222875A1 (en) 2020-04-30 2021-11-04 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6262247B1 (en) 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
CA2448382C (en) 2001-05-25 2013-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin as a regulator of iron homeostasis
CN1173737C (zh) 2002-10-21 2004-11-03 钱忠明 Hepcidin(海魄喜定)在制药中的应用
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
AU2003295644A1 (en) 2002-11-19 2004-07-22 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
JP2007518062A (ja) 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
US7723063B2 (en) 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
WO2006046935A1 (en) 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Methods of optimizing antibody variable region binding affinity
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP5069214B2 (ja) 2005-03-11 2012-11-07 ヴァーミリオン インコーポレイテッド 卵巣癌及び子宮内膜癌のバイオマーカー：ヘプシジン
AR065083A1 (es) * 2007-02-02 2009-05-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
ES2385772T3 (es) 2007-10-02 2012-07-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos específicos para la hepcidina humana
CL2008003190A1 (es) 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
US8609817B2 (en) * 2008-08-06 2013-12-17 Eli Lilly And Company Anti-hepcidin-25 selective antibodies and uses thereof

Also Published As

Publication number Publication date
PE20091261A1 (es) 2009-08-17
JP2011502482A (ja) 2011-01-27
PT2209806E (pt) 2012-10-03
MX2010004841A (es) 2010-07-30
AR069062A1 (es) 2009-12-23
MY155708A (en) 2015-11-13
EA023406B1 (ru) 2016-06-30
WO2009058797A1 (en) 2009-05-07
US20130164304A1 (en) 2013-06-27
TN2010000201A1 (en) 2011-11-11
US20110027261A1 (en) 2011-02-03
DOP2013000205A (es) 2013-12-15
MA31886B1 (fr) 2010-12-01
CL2012001710A1 (es) 2013-04-12
DK2209806T3 (da) 2012-09-17
US8765129B2 (en) 2014-07-01
JP5469076B2 (ja) 2014-04-09
KR20120107145A (ko) 2012-09-28
CY1113630T1 (el) 2016-06-22
IL205355A0 (en) 2010-12-30
HRP20120870T1 (hr) 2012-11-30
SI2209806T1 (sl) 2012-11-30
NZ584997A (en) 2012-06-29
CA2704527C (en) 2015-12-15
US8329174B2 (en) 2012-12-11
KR101335059B1 (ko) 2013-12-11
EP2527368A1 (en) 2012-11-28
ZA201003025B (en) 2011-11-30
BRPI0819211A2 (pt) 2015-06-16
RS52592B (sr) 2013-04-30
ES2392123T3 (es) 2012-12-04
PL2209806T3 (pl) 2013-01-31
EP2527368B1 (en) 2016-08-24
US7820163B2 (en) 2010-10-26
CA2704527A1 (en) 2009-05-07
CR11414A (es) 2010-08-05
KR20100067682A (ko) 2010-06-21
EP2209806B1 (en) 2012-08-22
AU2008318850A1 (en) 2009-05-07
CN103492414A (zh) 2014-01-01
US20090136495A1 (en) 2009-05-28
JO2828B1 (en) 2014-09-15
CO6231037A2 (es) 2010-12-20
CN103492414B (zh) 2016-04-13
HK1142341A1 (en) 2010-12-03
AU2008318850B2 (en) 2014-05-29
DOP2010000123A (es) 2010-08-15
IL205355A (en) 2015-05-31
EP2209806A1 (en) 2010-07-28
NZ598391A (en) 2013-07-26
CL2008003190A1 (es) 2009-09-04
EA201070553A1 (ru) 2010-10-29
TW200927759A (en) 2009-07-01
TWI409276B (zh) 2013-09-21

Similar Documents

Publication Publication Date Title
UA95068C2 (uk) Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
CA2844033C (en) Method for detecting pancreatic cancer
MY156315A (en) Anti-vegf antibodies
TN2014000120A1 (en) Cd27l antigen binding proteins
MX2009006277A (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
MX2010004660A (es) NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS.
UA97473C2 (uk) Виділене антитіло, яке зв'язується з her-3, та його застосування
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
PH12015501848A1 (en) Binding agents
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
MY174493A (en) Binding agents
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
MX2010008096A (es) Anticuerpos de ferroportina y metodos de uso.
UA94576C2 (uk) Виділене антитіло, яке зв'язується з igf-1r, композиція, що його містить, та способи, що стосуються антитіл
TNSN08548A1 (en) Prlr-specific antibody and uses thereof
MX2014005546A (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
WO2009088924A3 (en) Methods and materials for targeted affinity enhancement
WO2009113814A3 (ko) 간암 진단용 단백질성 마커
EA200901421A1 (ru) Антитела к il-25
MX2010001237A (es) Nuevos anticuerpos.
WO2011055968A3 (en) Kit for detecting bacterial infection comprising novel monoclonal antibodies
MX2009001341A (es) Anticuerpos especificos de ephb3 y usos de los mismos.